ES557836A0 - Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables. - Google Patents

Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.

Info

Publication number
ES557836A0
ES557836A0 ES557836A ES557836A ES557836A0 ES 557836 A0 ES557836 A0 ES 557836A0 ES 557836 A ES557836 A ES 557836A ES 557836 A ES557836 A ES 557836A ES 557836 A0 ES557836 A0 ES 557836A0
Authority
ES
Spain
Prior art keywords
deoxythimidine
azido
preparing
procedure
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES557836A
Other languages
English (en)
Other versions
ES8802616A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26288986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES557836(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB858506869A external-priority patent/GB8506869D0/en
Priority claimed from GB858511774A external-priority patent/GB8511774D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of ES8802616A1 publication Critical patent/ES8802616A1/es
Publication of ES557836A0 publication Critical patent/ES557836A0/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES557836A 1985-03-16 1988-04-29 Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables. Expired ES8802616A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858506869A GB8506869D0 (en) 1985-03-16 1985-03-16 Antiviral compound
GB858511774A GB8511774D0 (en) 1985-05-09 1985-05-09 Antiviral compounds

Publications (2)

Publication Number Publication Date
ES8802616A1 ES8802616A1 (es) 1988-09-01
ES557836A0 true ES557836A0 (es) 1988-09-01

Family

ID=26288986

Family Applications (2)

Application Number Title Priority Date Filing Date
ES557836A Expired ES8802616A1 (es) 1985-03-16 1988-04-29 Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
ES557835A Expired ES8802615A1 (es) 1985-03-16 1988-04-29 Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557835A Expired ES8802615A1 (es) 1985-03-16 1988-04-29 Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.

Country Status (2)

Country Link
US (9) US4724232A (es)
ES (2) ES8802616A1 (es)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093114A (en) * 1985-03-16 1992-03-03 Burroughs Wellcome Co. Treatment of human viral infections
US5683990A (en) * 1985-03-16 1997-11-04 Glaxo Wellcome Inc. Treatment of human viral infections
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
ATE190064T1 (de) * 1985-09-17 2000-03-15 Wellcome Found Kombination therapeutische nukleoside mit weiteren therapeutisch wirksamen komponenten.
US4841039A (en) * 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US5084445A (en) * 1986-05-01 1992-01-28 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5077279A (en) * 1986-05-01 1991-12-31 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
US5086044A (en) * 1986-06-23 1992-02-04 Burroughs Wellcome Co. Treatment of human viral infections
SE8602981D0 (sv) 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
US5190926A (en) * 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
EP0286825A3 (en) * 1987-03-18 1989-04-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US5187163A (en) * 1987-03-27 1993-02-16 Baker Norton Pharmaceuticals, Inc. Anti-viral compounds, dosage forms and methods
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
IL86007A0 (en) * 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4837311A (en) * 1987-06-22 1989-06-06 Hoffman-La Roche Inc. Anti-retroviral compounds
USRE33887E (en) * 1987-06-22 1992-04-14 Hoffmann-La Roche Inc. Anti-retroviral compounds
US4900548A (en) * 1987-11-13 1990-02-13 Harvard University Use of diethylcarbamazine to enhance antigen-antibody and antigen-host immune cell interactions
WO1989005152A1 (en) * 1987-12-09 1989-06-15 The Regents Of The University Of California Liposome-encapsulated anti-viral composition and method
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
US5025800A (en) * 1988-01-26 1991-06-25 Zelson Steve T Contraceptive device
WO1989009055A1 (en) * 1988-03-23 1989-10-05 New York University Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
WO1989009056A1 (en) * 1988-03-23 1989-10-05 New York University Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
JPH02504641A (ja) * 1988-06-10 1990-12-27 バイオジェン インコーポレイテッド 可溶性ｔ４蛋白質と抗レトロウィルス剤との組合せ並びにａｉｄｓ、ａｒｃおよびｈｉｖ感染の処置または防止方法
US5122517A (en) * 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
IL93682A (en) * 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
US5686428A (en) * 1989-04-07 1997-11-11 Aktiebolaget Astra Pharmaceutical composition
JP2831030B2 (ja) * 1989-05-12 1998-12-02 学校法人城西大学 ３’‐アジド‐３’デオキシチミジンを有効成分とする経皮投与製剤用組成物
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
US5116823A (en) 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT
WO1991013623A1 (en) * 1990-03-09 1991-09-19 Memorial Hospital For Cancer And Allied Diseases C-5 mono-substituted barbiturates in combination with therapeutic agents and uses thereof
US5137724A (en) * 1990-05-23 1992-08-11 Stichting Rega Vzw Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5276143A (en) * 1990-12-21 1994-01-04 E. I. Du Pont De Nemours And Company Dideoxyfructonucleosides and deoxyfructonucleotides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5220003A (en) * 1991-03-29 1993-06-15 The Regents Of The University Of California Process for the synthesis of 2',3'-dideoxynucleosides
US5221669A (en) * 1991-04-19 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
US5633235A (en) * 1991-04-19 1997-05-27 Regents Of The University Of Michigan Triciribine and analogs as antiviral drugs
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
AU2181592A (en) * 1991-06-21 1993-01-25 Acic (Canada) Inc. Novel anti-viral compounds and processes for production of anti-viral compounds
US5599930A (en) * 1991-07-03 1997-02-04 The Upjohn Company Substituted indoles as anti-AIDS pharmaceuticals
IL102548A (en) * 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
JP2711182B2 (ja) * 1992-08-19 1998-02-10 シェリング・コーポレーション Ｉｌ−４を用いるｈｉｖ複製を阻害する方法
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
AU5960894A (en) * 1992-12-29 1994-07-19 Rolland Chen Treatment of viral infections
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5576355A (en) * 1993-06-04 1996-11-19 Mobil Oil Corp. Diamondoid derivatives for pharmaceutical use
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2637774C (en) * 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
EP1247804A1 (en) * 1993-11-12 2002-10-09 PHARMACIA & UPJOHN COMPANY Pyrimidine-thioalkyl and alkylether compounds
US5466787A (en) * 1993-11-15 1995-11-14 Bristol-Myers Squibb Company Process for preparing AZT
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
DE69535758D1 (de) * 1994-08-29 2008-07-03 Univ Wake Forest Lipid-analoge zur behandlung von viralen infektionen
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US6689761B1 (en) * 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
US6576622B1 (en) * 1995-03-14 2003-06-10 University Of Medicine & Dentistry Of New Jersey Drug combination for the treatment of viral diseases
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
UA56992C2 (uk) * 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
WO1996040164A1 (en) * 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
ATE459361T1 (de) 1995-09-07 2010-03-15 Univ Georgia Therapeutische azidverbindungen
CA2189097A1 (en) 1995-11-15 1997-05-16 Pin-Fang Lin Composition and method of treating retroviral infection
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
CZ429398A3 (cs) * 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
DE19632823C1 (de) * 1996-08-14 1997-11-20 Symbio Herborn Group Gmbh & Co Komplexe zwischen S-(+)-Adenosylmethionin und 3'-Azido-2',3'-didesoxynucleosid als potente Inhibitoren der HIV-Replikation
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO1999019304A2 (en) * 1997-09-25 1999-04-22 Pharmacia & Upjohn Company Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors
US6040434A (en) * 1997-12-01 2000-03-21 Inaba; Tadanobu Aldehyde oxidase inhibitors for treatment of aids
US6136814A (en) * 1997-12-08 2000-10-24 Fujisawa Usa, Inc. Aqueous acyclovir product
WO1999033477A1 (en) * 1997-12-24 1999-07-08 Visible Genetics Inc. Drug-directed mutagenesis/drug-driven selection for lethal mutants
WO1999048371A1 (en) * 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
US6309632B1 (en) 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
WO2000016625A1 (en) * 1998-09-23 2000-03-30 University Of Kentucky Research Foundation Antiviral drug compositions containing lithium inorganic salts
AU763289C (en) * 1998-11-06 2004-04-29 Schering Aktiengesellschaft Use of GM-CSF to inhibit development of drug resistance in HIV+ patients
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6511983B1 (en) * 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US6107303A (en) * 1999-03-15 2000-08-22 Demarco; Charlene C. Treatment of Epstein Barr infection
US7186736B1 (en) * 1999-03-20 2007-03-06 Parker Hughes Institute NNI for treatment of multi-drug resistant HIV
JP2002540149A (ja) * 1999-03-31 2002-11-26 ザ プロクター アンド ギャンブル カンパニー ウイルス感染治療のためのカルバミン酸エステル誘導体の使用法
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
IT1318424B1 (it) * 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
US20030171406A1 (en) * 2000-06-13 2003-09-11 Akihiko Sato Medicinal compositions containing propenone derivatives
US7012086B1 (en) * 2000-06-30 2006-03-14 The Foundation For Innovative Therapies, Inc. Treatment of retrovirus induced derangements with niacin compounds
GB0016845D0 (en) * 2000-07-07 2000-08-30 Leuven K U Res & Dev Pharmaceutical composition for treatment of HIV infection
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
US20050049242A1 (en) * 2000-12-21 2005-03-03 W. Edward Robinson Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
CN1486289A (zh) * 2001-05-29 2004-03-31 皇家菲利浦电子有限公司 金属-陶瓷的结合
WO2003016472A2 (en) * 2001-08-12 2003-02-27 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
IL160080A0 (en) * 2001-08-31 2004-06-20 Thomson Licensing Sa Sequence counter for an audio visual stream
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
RU2293739C2 (ru) * 2002-07-26 2007-02-20 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" 5`-холинфосфат 3`-азидо-3`-дезокситимидина как антивирусный агент
DE60313657T2 (de) * 2002-11-08 2008-01-03 Smithkline Beecham Corp. Antivirale zusammensetzungen
US20040182427A1 (en) * 2003-03-19 2004-09-23 Goettl John M. Method and apparatus for channeling debris in a swimming pool
US20050113331A1 (en) * 2003-09-09 2005-05-26 Michael Prniak Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
ME03423B (me) 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
LV13544B (en) 2005-08-15 2007-05-20 Grindeks As Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium
DE102006037786A1 (de) * 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010049438A2 (en) * 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
EP2376514A2 (en) * 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
NZ593648A (en) * 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
US8518409B2 (en) 2010-05-31 2013-08-27 Imperium Biotechnologies, Inc. System for selective cell treatment using ideotypically modulated pharmacoeffectors
US8383405B2 (en) 2010-05-31 2013-02-26 Imperium Biotechnologies, Inc. Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
JP7121731B2 (ja) * 2016-09-26 2022-08-18 タフツ・ユニバーシティ ウリジンヌクレオシド誘導体、組成物及び使用方法
JP2021509907A (ja) 2018-01-09 2021-04-08 リガンド・ファーマシューティカルズ・インコーポレイテッド アセタール化合物およびその治療的使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963998A1 (de) * 1968-12-24 1970-11-12 Takeda Chemical Industries Ltd Interferon induzierendes Mittel,Verfahren zu seiner Herstellung und Verfahren zur Interferon-Induktion durch Verwendung dieses Mittels
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4230698A (en) * 1978-05-12 1980-10-28 Research Corporation 2-Substituted arabinofuranosyl nucleosides and nucleotides
US4695570A (en) * 1982-10-14 1987-09-22 Burroughs Wellcome Co. Antiviral compound use
US4649140A (en) * 1982-10-14 1987-03-10 Burroughs Wellcome Co. Purine derivatives
SE8406538D0 (sv) * 1984-12-21 1984-12-21 Astra Laekemedel Ab Novel derivatives of purine
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4723232A (en) * 1987-01-27 1988-02-02 Beebe William B Pendulum indicator horological device
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide

Also Published As

Publication number Publication date
ES557835A0 (es) 1988-09-01
US4874609A (en) 1989-10-17
US4780453A (en) 1988-10-25
US5885957A (en) 1999-03-23
US5643891A (en) 1997-07-01
ES8802616A1 (es) 1988-09-01
US4818538A (en) 1989-04-04
ES8802615A1 (es) 1988-09-01
US4724232A (en) 1988-02-09
US4833130A (en) 1989-05-23
US4837208A (en) 1989-06-06
US4828838A (en) 1989-05-09

Similar Documents

Publication Publication Date Title
ES557836A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3&#39;-azido-3&#39;-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
MX9200180A (es) DERIVADOS DE LA 5H-PIRROL (3,4-b) PIRAZINA OPTICAMENTE ACTIVOS, PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LOS CONTIENE.
MX9202934A (es) Derivados de carbostirilo y composicion farmaceutica que los contiene.
NO882075L (no) 9-alfa-hydroksysteroider, deres fremstilling, en fremgangsmaate for fremstilling av de tilsvarende 9(11)-dehydroderivater samt farmasoeytiske preparater inneholdende forbindelsene.
KR900701258A (ko) 결장 선택적 방출성을 갖는 경구용 약제학적 제제
MX9202619A (es) Derivados de oxa tiolano cristalino, metodo para su preparacion y formulacion farmaceutica que los contiene.
DK128688D0 (da) Thiazolderivater og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende derivaterne
DK160981C (da) Arylsulfonylurinstof-derivater, fremgangsmaade til fremstilling deraf, anvendelse af disse som terapeutisk og antineoplastisk middel samt farmaceutiske midler indeholdende saadanne derivater
DK343388D0 (da) 2,2-dimethylchroman-3-ol-derivater og fremgangsmaade til fremstilling deraf, farmaceutiske midler indeholdende derivaterne samt disse anvendelse til fremstilling af farmaceutiske midler
ES552297A0 (es) Un procedimiento para la preparacion de nuevos derivados de disacaridos o trisacaridos.
SE8900346L (sv) Farmaceutisk komposition som innehaaller ett plantextrakt samt foerfarande foer framstaellning av detsamma
DK112287A (da) Anvendelse af 2-alkoxy-n-(1-azabicyclo-oe2,2,2aaoct-3-yl)-benzamider og -thiobenzamider samt farmaceutisk acceptable syreadditionssalte deraf som laegemidler
DK645788D0 (da) Anvendelse af ergolinderivater til fremstilling af et farmaceutisk praeparat
NO874850D0 (no) Fremgangsmaate for fremstilling av benzotiadiazinforbindelser og farmasoeytisk akseptable salter derav.
MX9202763A (es) Nuevos derivados de 2-(1-piperazinil)-4-fenil-cicloalcanopiridina y composicion farmaceutica que los contiene.
DK635988D0 (da) 1,3-butandiolacetoacetat-derivater og anvendelse af 1,3-butandiolacetoacetat-forbindelser til fremstilling af farmaceutiske praeparater
PT87679A (pt) A process for the preparation of 2-methoxymethyl-penem derivatives and of pharmaceutical compositions containing the same
ES538606A0 (es) Un procedimiento para preparar una sustancia antibiotica seleccionada del antibiotico l 17054 y sus sales por adicion de acidos farmaceuticamente acepatables
ES557209A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3&#39;-azido-3&#39;-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
ES557834A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3&#39;-azido-3&#39;-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
ES551866A0 (es) Procedimiento de preparacion de nuevos derivados alquilamino-furanonas y de sales y diastereoisomeros farmaceuticamente aceptables de los mismos.
MX7715E (es) Procedimiento para la preparacion de una composicion farmaceutica a base de microgranulos que contiene sulpirida
DK273187A (da) Farmaceutiske praeparater indeholdende naphthyridinderivater
PH24057A (en) 7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-ene derivatives,pharmaceutical composition containing said compounds and method of use thereof
DK492289A (da) 3-aryloxymethyl-cephalosporinderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende derivaterne